죽상경화성 심혈관질환 - 시장 인사이트, 역학, 시장 예측(2036년)

ASCVD Insights and Trends

• ASCVD prevalence continues to rise across the 7MM due to population aging, improved post-event survival, and sustained exposure to cardiometabolic risk factors, expanding the long-term secondary prevention pool.
• The burden of ASCVD increases sharply with age. Prevalence is significantly higher in older adults, particularly among medically insured populations, where comorbidity levels and cardiovascular risk factors accumulate. Younger commercial populations, though affected, display comparatively lower disease severity.
• Pharmacologic management of ASCVD continues to center on statins, ezetimibe, antiplatelets, and cardiometabolic therapies, with PCSK9-targeted agents Evolocumab, Alirocumab, and Inclisiran, providing established options for patients who require additional LDL-C reduction.
• The evolving late-stage and emerging pipeline, encompassing oral PCSK9 inhibitors, RNA-based Lp (a) therapies, anti-inflammatory agents, and gene-editing approaches, is driving a shift toward multi-pathway, precision management, offering the potential to reduce residual cardiovascular risk, improve adherence, and expand therapeutic options for high-risk patients.
• Despite guideline-directed care, residual inflammatory risk, incomplete LDL control, comorbidity load, and access gaps to advanced therapies remain major unmet needs limiting real-world secondary prevention impact.
• Among 7MM, the United States accounted for the highest market size of ASCVD, with Germany being the second highest contributor for ASCVD total market size. The total market size of ASCVD in the 7MM was USD 24,000 million in 2025, which is expected to grow by 2036.
• REPATHA's growth continues to accelerate 10 years post-launch and it currently dominates the PCSK9 inhibitor market; however, LEQVIO and emerging oral PCSK9 therapies are projected to capture a larger share by 2036, particularly as inclisiran patents in the United States and Europe expire in 2034 and 2035, respectively.

ASCVD Market size and forecast (7MM)

• 2025 ASCVD Market Size: ~USD 24,000 million
• 2036 Projected ASCVD Market Size: ~USD 40,000 million
• ASCVD Growth Rate (2026-2036): 4.8% CAGR

DelveInsight's 'Atherosclerotic Cardiovascular Disease (ASCVD)- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the ASCVD, historical and forecasted epidemiology, as well as the ASCVD market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The ASCVD market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, ASCVD patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in ASCVD and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the ASCVD Market

• Expanding global cardiovascular disease burden sustaining large market opportunity.
• Persistent residual risk despite statin therapy driving demand for adjunctive treatments.
• Broadening treatable populations through earlier intervention and high-risk subgroups.

ASCVD Understanding and Treatment Algorithm

ASCVD Overview and Diagnosis

ASCVD is a medical condition characterized by the buildup of fatty deposits (plaques) on the inner walls of arteries. These plaques consist of cholesterol, fatty substances, calcium, and other cellular waste products. Over time, the plaques can harden and narrow the arteries, which reduces blood flow to vital organs and tissues. It is a progressive and chronic condition that can affect various arteries throughout the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and legs (peripheral arteries). The most common manifestations of ASCVD include Coronary Artery Disease (CAD), cerebrovascular disease (stroke), and Peripheral Arterial Disease (PAD).

ASCVD Diagnosis

Diagnosis of ASCVD is based on a combination of clinical evaluation, laboratory tests, genetic analysis, and imaging techniques. Initial assessment typically includes lipid profile testing measuring total cholesterol, LDL-C, HDL-C, and triglycerides along with additional biomarkers such as apolipoproteins, hsCRP, and lipoprotein (a) in selected patients to refine cardiovascular risk. Genetic testing may be used in individuals with suspected familial hypercholesterolemia by evaluating genes such as LDLR, APOB, PCSK9, or LDLRAP1. Imaging methods including ultrasonography, CT, MRI/MRA, and invasive catheter angiography help detect arterial plaques, stenosis, or calcification, while electrocardiography can identify reduced blood flow to the heart. Regular lipid monitoring is recommended to evaluate treatment response and guide risk-based lipid management.

ASCVD Treatment

Management and prevention of ASCVD primarily focus on lifestyle modification, pharmacotherapy, and interventional procedures. A healthy lifestyle including a balanced diet rich in fruits, vegetables, whole grains, and fish, regular physical activity, and avoidance of tobacco is the cornerstone of ASCVD prevention and risk reduction. Pharmacologic treatment is recommended for higher-risk individuals and commonly includes statins as first-line therapy, with additional agents such as ezetimibe, PCSK9 inhibitors, and omega-3 fatty acids when lipid control is inadequate. In patients with established disease or severe coronary artery blockage, revascularization procedures such as percutaneous coronary intervention (angioplasty with stent placement) or coronary artery bypass grafting may be used to restore blood flow and reduce cardiovascular complications.

ASCVD Unmet Needs

The section "unmet needs of ASCVD" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Inflammation in ASCVD is not adequately addressed by current therapies

2. Patients need treatments with a low risk of Drug-Drug interactions

3. Strong dependence on clinician recommendation for treatment adoption

4. Incomplete lipid target achievement and others.....

Comprehensive unmet needs insights in ASCVD and their strategic implications are provided in the full report.

ASCVD Epidemiology

Key Findings from ASCVD Epidemiological Analysis and Forecast

• As per the estimates by DelveInsight, the total diagnosed prevalent cases of ASCVD in the 7MM was 65,415,000 in 2025.
• In 2025, approximately 55% of ASCVD cases in the US occurred in males and 45% in females, accounting for around 17,300,000 male cases and 13,800,000 female cases.
• Different age groups are counted for DelveInsight's epidemiology model; ASCVD is categorized into age groups 18-44 years, 45-64 years, and 65 years and above. Among these age groups, the 65 and above age group was estimated to have the highest number of diagnosed ASCVD cases in EU4 and the UK in 2025. The number of diagnosed cases for 65+ age groups was approximately 15,900,000; however, it should be noted that the least number of cases were found in patients aged 18-44 years in 2025.
• As per DelveInsight's analysis, the comorbidity-specific diagnosed prevalent cases of ASCVD in Japan in 2025 were highest for Peripheral Artery Disease (PAD) at approximately 1,936,000 cases, while the lowest prevalence was observed in Acute Coronary Syndrome (ACS) with about 102,000 cases.

ASCVD Drug Chapters & Competitive Analysis

The ASCVD drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the ASCVD treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the ASCVD therapeutics market.

Approved Therapies for ASCVD

Evolocumab (REPATHA): Amgen

REPATHA is a human immunoglobulin G2 (IgG2) monoclonal antibody directed against human PCSK9. REPATHA has an approximate molecular weight of 144 kDa and is produced in genetically engineered mammalian cells. It binds to PCSK9 and inhibits circulating PCSK9 from binding to the LDL receptor, preventing PCSK9-mediated LDL receptor degradation and permitting the LDL receptor to recycle back to the liver cell surface. By this inhibition, REPATHA increases the number of LDL receptors available to clear LDL from the blood, thereby lowering LDL-C levels.

It was first approved in 2015 in the US and Europe for patients with hypercholesterolemia and ASCVD requiring additional LDL-C reduction. It was approved in Japan in 2016 for high-risk hypercholesterolemia patients, with later label expansions, including a 2025 US update for adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL-C.

ASCVD Pipeline Analysis

Olpasiran (AMG 890): Amgen/Arrowhead Pharmaceuticals

Olpasiran is an investigational siRNA therapy developed by Amgen to reduce elevated Lp (a) levels in adults with ASCVD. It functions by reducing Lp (a) production in liver cells through RNA interference, specifically inhibiting Lp(a) expression. It leverages siRNA technology, originally advanced from Arrowhead Pharmaceuticals, to achieve potent, dose-dependent Lp(a) lowering

The drug is currently being evaluated in two Phase III trials for the treatment of ASCVD in patients with elevated Lp (a). Additionally, a Phase III primary prevention study in patients with elevated Lp (a) who are at high risk for a first cardiovascular event has been initiated in H2 2025

ASCVD Key Players, Market Leaders and Emerging Companies

• Amgen/Arrowhead Pharmaceuticals
• NewAmsterdam Pharma and Menarini Group
• Resverlogix
• Ionis Pharmaceuticals/Novartis
• LIB Therapeutics
• Sanofi/ Regeneron Pharmaceuticals, and others

ASCVD Drug Updates

• In January 2025, Ionis Pharmaceuticals' partner Novartis announced in its year-end earnings report that Phase III pelacarsen data are now expected in the first half of 2026, with regulatory submissions planned for the second half of the year.
• In January 2025, LIB Therapeutics announced the publication of a Phase III study of lerodalcibep in HoFH in The lancet diabetes and Endocrinology.
• In September 2025, Menarini Group announced that EMA has validated the Marketing Authorization Application (MAA) for obicetrapib and obicetrapib/ezetimibe fixed dose combination as an adjunct to diet for patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia and unable to reach low-density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or who are statin-intolerant, or for whom a statin is contraindicated. The validation of both applications confirms that the submission is complete and begins the EMA's centralized review procedure.

ASCVD Market Outlook

The treatment landscape for ASCVD is primarily driven by lipid-lowering therapies aimed at reducing LDL-C levels, supported by antiplatelet, anticoagulant, and anti-inflammatory agents for both primary and secondary prevention. Statins remain the cornerstone of therapy, while additional treatments such as ticagrelor, rivaroxaban, and LODOCO (low-dose colchicine) play key roles in reducing thrombotic and inflammatory cardiovascular risks. Among advanced lipid-lowering options, PCSK9-targeted therapies including evolocumab, alirocumab, and the siRNA therapy inclisiran, have significantly improved LDL-C control in high-risk patients requiring additional lipid reduction beyond statins. Evolocumab currently leads the PCSK9 market, while inclisiran is gaining traction due to its twice-yearly dosing and potential adherence advantages. Other lipid-modifying therapies such as bempedoic acid and icosapent ethyl further address residual cardiovascular risk. Despite strong clinical efficacy, uptake of advanced lipid-lowering therapies remains limited due to cost and reimbursement barriers; however, increasing payer alignment and the development of next-generation therapies including oral PCSK9 inhibitors, RNA-based agents targeting lipoprotein(a), and gene-editing approaches are expected to expand treatment options and reshape the ASCVD market in the coming years.

Key players involved in developing targeted therapies to treat ASCVD include Amgen/Arrowhead Pharmaceuticals (olpasiran), NewAmsterdam Pharma and Menarini Group (obicetrapib), Resverlogix (apabetalone), Ionis Pharmaceuticals/Novartis (pelacarsen), LIB Therapeutics (lerodalcibep), AstraZeneca (laroprovstat), and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of ASCVD.

• The total market size of ASCVD in the 7MM is approximately USD 24,000 million in 2025 and is projected to increase during the forecast period (2026-2036).
• Among EU4 and the UK, Germany accounts for the maximum market size in 2025, while France occupies the bottom of the ladder in 2025.
• In 2025, among the current therapies for ASCVD, the largest revenue was generated by Evolocumab, i.e., ~USD 1,500 million in the United States.
• By 2036, among the emerging therapies anticipated to enter the therapeutic market of ASCVD, statin therapies is expected to generate the highest revenue in Japan.

Drug Class/Insights

The treatment landscape for ASCVD is dominated by several major drug classes that target lipid reduction, thrombosis prevention, and vascular inflammation. Statins remain the first-line therapy for lowering LDL-C and reducing cardiovascular risk, while additional lipid-lowering agents such as bempedoic acid and omega-3 based therapies like icosapent ethyl are used to address residual lipid-related risk. For patients requiring further LDL-C reduction, PCSK9 inhibitors have emerged as an important class, including therapies such as inclisiran and others. In parallel, antiplatelet agents such ticagrelor and anticoagulants like rivaroxaban play a critical role in preventing thrombotic events in high-risk patients. More recently, anti-inflammatory therapies, including low-dose colchicine, have gained attention for targeting vascular inflammation, an important contributor to residual cardiovascular risk. Together, these drug classes form a comprehensive treatment strategy that addresses the multiple pathophysiological mechanisms involved in ASCVD progression and recurrence.

ASCVD Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2022-2036. For example, for Olpasiran, although the FDA rescinded its Fast Track Designation, we expect the drug uptake to be medium-fast with a probability-adjusted peak share of 3.5% and years to the peak are expected to be 7 years from the year of launch.

ASCVD Therapies Price Scenario & Trends

Pricing and analogue assessment of ASCVD therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of ASCVD Approved Drugs

Ezetimibe, bempedoic acid, and their fixed-dose combinations are widely used in the treatment of ASCVD. The average price of one tablet of ezetimibe is estimated at USD 3 and is prescribed as a once-daily dose. Based on this pricing, the annual cost of ezetimibe and its combination therapies is estimated at USD 1,104. Bempedoic acid is also prescribed as a once-daily dose and is priced at approximately USD 11 per tablet. Accordingly, the annual cost of bempedoic acid therapy is estimated at USD 3,991.

Further details are provided in the final report....

Industry Experts and Physician Views for ASCVD

To keep up with ASCVD market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on ASCVD emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in ASCVD, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

Delveinsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Jacksonville Center for Clinical Research, University of Louisville School of Medicine, and Yale School of Medicine etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or ASCVD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of ASCVD, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of ASCVD, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the ASCVD market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM ASCVD market.

Report Insights

• ASCVD patient population forecast
• ASCVD therapeutics market size
• ASCVD pipeline analysis
• ASCVD market size and trends
• ASCVD market opportunity (current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) bottom-up forecasting
• Artificial Intelligence (AI)-enabled market research report
• 11-year forecast
• ASCVD market outlook (North America, Europe, Asia-Pacific)
• Patient Burden trends (by geography)
• ASCVD Treatment addressable Market (TAM)
• ASCVD Competitive Landscape
• ASCVD major companies Insights
• ASCVD Price trends and analogue assessment
• ASCVD Therapies Drug Adoption/Uptake
• ASCVD Therapies Peak Patient Share analysis

Report Assessment

• ASCVD Current treatment practices
• ASCVD Unmet needs
• ASCVD Clinical development Analysis
• ASCVD emerging drugs product profiles
• ASCVD Market attractiveness
• ASCVD Qualitative analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the ASCVD market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of ASCVD?
• What are the disease risks, burdens, and unmet needs of ASCVD? What will be the growth opportunities across the 7MM concerning the patient population with ASCVD?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of ASCVD? What are the current guidelines for treating ASCVD in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the ASCVD market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences and Meetings
• 4.3. Key Transactions and Collaborations
• 4.4. News Flow

5. Epidemiology and Market Forecast Methodology

6. Atherosclerotic Cardiovascular Disease (ASCVD) Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of ASCVD by Therapies in 7MM, in 2025
• 6.3. Market Share (%) Distribution of ASCVD by Therapies in 7MM, in 2036

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Associated Diseases
• 7.3. Pathophysiology of Atherosclerosis
• 7.4. Risk Factors of ASCVD
• 7.5. Symptoms of ASCVD
• 7.6. Diagnosis
  • 7.6.1. Risk Assessment
  • 7.6.2. Diagnostic Guidelines
    • 7.6.2.1. Kaiser Permanente Washington Guideline for Management of ASCVD
    • 7.6.2.2. ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease: 2019
    • 7.6.2.3. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
    • 7.6.2.4. ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2021

8. Treatment of ASCVD

• 8.1. Treatment Algorithm
• 8.2. Treatment Guidelines
  • 8.2.1. ACC/AHA Guidelines on the Primary Prevention of ASCVD: 2019
  • 8.2.2. Major Treatment Recommendations of the 2018 AHA/ACC Multisociety Cholesterol Guideline and the 2019 ESC/EAS Guidelines for Secondary ASCVD Prevention
  • 8.2.3. Kaiser Permanente Washington Guideline for the Management of ASCVD
  • 8.2.4. Japan Atherosclerosis Society (JAS) Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2017
  • 8.2.5. ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2021

9. Epidemiology and Patient Population of ASCVD

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Diagnosed Prevalent Cases of ASCVD in the 7MM
• 9.4. The United States
  • 9.4.1. Total Diagnosed Prevalent Cases of ASCVD in the US
  • 9.4.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in the US
  • 9.4.3. Age-specific Diagnosed Prevalent Cases of ASCVD in the US
  • 9.4.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in the US
  • 9.4.5. Systemic inflammation in ASCVD in the US
• 9.5. EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Cases of ASCVD in EU4 and the UK
  • 9.5.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in EU4 and the UK
  • 9.5.3. Age-specific Diagnosed Prevalent Cases of ASCVD in EU4 and the UK
  • 9.5.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in EU4 and the UK
  • 9.5.5. Systemic inflammation in ASCVD in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Diagnosed Prevalent Cases of ASCVD in Japan
  • 9.6.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in Japan
  • 9.6.3. Age-specific Diagnosed Prevalent Cases of ASCVD in Japan
  • 9.6.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in Japan
  • 9.6.5. Systemic Inflammation in ASCVD in Japan

10. Patient Journey of ASCVD

11. Marketed Therapies

• 11.1. Key Cross Competition
• 11.2. Evolocumab (REPATHA): Amgen
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trial
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical trials information
  • 11.2.6. Analyst Views
• 11.3. Inclisiran (LEQVIO): Novartis/Alnylam Pharmaceuticals
  • 11.3.1. Drug Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trial
  • 11.3.5. Clinical Development
    • 11.3.5.1. Clinical trials information
  • 11.3.6. Analyst's View
• 11.4. Alirocumab (PRALUENT): Sanofi/Regeneron Pharmaceuticals
  • 11.4.1. Drug Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Other Developmental Activities
  • 11.4.4. Summary of Pivotal Trial
  • 11.4.5. Analyst's View
• 11.5. Bempedoic acid (NEXLETOL/NILEMDO): Esperion Therapeutics/Daiichi Sankyo/Otsuka
  • 11.5.1. Drug Description
  • 11.5.2. Regulatory Milestones
  • 11.5.3. Other Developmental Activities
  • 11.5.4. Summary of Pivotal Trials
  • 11.5.5. Analyst's View
• 11.6. Bempedoic acid and ezetimibe (NEXLIZET/NUSTENDI): Esperion Therapeutics/Daiichi Sankyo
  • 11.6.1. Product Description
  • 11.6.2. Regulatory Milestones
  • 11.6.3. Other Developmental Activities
  • 11.6.4. Summary of Pivotal Trials
  • 11.6.5. Analyst's View
• 11.7. Rivaroxaban (XARELTO): Bayer/Johnson & Johnson
  • 11.7.1. Product Description
  • 11.7.2. Regulatory Milestones
  • 11.7.3. Other Developmental Activities
  • 11.7.4. Summary of Pivotal Trials
  • 11.7.5. Safety and Efficacy
  • 11.7.6. Analyst's View
• 11.8. Colchicine (Low-Dose Colchicine, LoDoCo): AGEPHA Pharma
  • 11.8.1. Product Description
  • 11.8.2. Regulatory Milestones
  • 11.8.3. Other Developmental Activities
  • 11.8.4. Summary of Pivotal Trials
  • 11.8.5. Analyst's View
• 11.9. Ticagrelor (BRILINTA): AstraZeneca
  • 11.9.1. Product Description
  • 11.9.2. Regulatory Milestones
  • 11.9.3. Other Developmental Activities
  • 11.9.4. Summary of Pivotal Trials
  • 11.9.5. Analyst's View
• 11.1. Icosapent ethyl (VASCEPA/VAZKEPA): Amarin Pharmaceuticals
  • 11.10.1. Product Description
  • 11.10.2. Regulatory Milestones
  • 11.10.3. Other Developmental Activities
  • 11.10.4. Summary of Pivotal Trials
  • 11.10.5. Analyst's View
• 11.11. Semaglutide oral (RYBELSUS): Novo nordisk
  • 11.11.1. Product Description
  • 11.11.2. Regulatory Milestones
  • 11.11.3. Summary of Pivotal Trials
  • 11.11.4. Analyst's View

12. Emerging Therapies

• 12.1. Key Cross Competition
• 12.2. Olpasiran (AMG 890): Amgen/Arrowhead Pharmaceuticals
  • 12.2.1. Drug Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trial Information
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst's View
• 12.3. Obicetrapib (TA-8995): NewAmsterdam Pharma and Menarini Group
  • 12.3.1. Drug Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trial Information
  • 12.3.4. Safety and Efficacy
  • 12.3.5. Analyst's View
• 12.4. Apabetalone (RVX000222): Resverlogix
  • 12.4.1. Drug Description
  • 12.4.2. Other Developmental Activities
  • 12.4.3. Clinical Development
    • 12.4.3.1. Clinical Trial Information
  • 12.4.4. Safety and Efficacy
  • 12.4.5. Analyst's View
• 12.5. Pelacarsen (TQJ230): Ionis Pharmaceuticals/Novartis
  • 12.5.1. Drug Description
  • 12.5.2. Other Developmental Activities
  • 12.5.3. Clinical Development
    • 12.5.3.1. Clinical Trial Information
  • 12.5.4. Safety and Efficacy
  • 12.5.5. Analyst's View
• 12.6. Lerodalcibep (LIB-003): LIB Therapeutics
  • 12.6.1. Drug Description
  • 12.6.2. Other Developmental Activities
  • 12.6.3. Clinical Development
    • 12.6.3.1. Clinical Trial Information
  • 12.6.4. Safety and Efficacy
  • 12.6.5. Analyst's View
• 12.7. Laroprovstat (AZD0780): AstraZeneca
  • 12.7.1. Drug Description
  • 12.7.2. Other Developmental Activities
  • 12.7.3. Clinical Development
    • 12.7.3.1. Clinical Trial Information
  • 12.7.4. Safety and Efficacy
  • 12.7.5. Analyst's View
• 12.8. Enlicitide Decanoate (MK-0616): Merck
  • 12.8.1. Drug Description
  • 12.8.2. Other Developmental Activities
  • 12.8.3. Clinical Development
    • 12.8.3.1. Clinical Trial Information
  • 12.8.4. Safety and Efficacy
  • 12.8.5. Analyst's View
• 12.9. Maridebart Cafraglutide (MariTide/formerly AMG 133): Amgen
  • 12.9.1. Drug Description
  • 12.9.2. Other Developmental Activities
  • 12.9.3. Clinical Development
    • 12.9.3.1. Clinical Trial Information
  • 12.9.4. Analyst's View
• 12.1. Orforglipron (LY3502970): Eli Lilly
  • 12.10.1. Drug Description
  • 12.10.2. Other Developmental Activities
  • 12.10.3. Clinical Development
    • 12.10.3.1. Clinical Trial Information
  • 12.10.4. Analyst's View
• 12.11. Muvalaplin (LY3473329): Eli Lilly
  • 12.11.1. Drug Description
  • 12.11.2. Other Developmental Activities
  • 12.11.3. Clinical Development
    • 12.11.3.1. Clinical Trial Information
  • 12.11.4. Safety and Efficacy
  • 12.11.5. Analyst's View
• 12.12. Retatrutide (LY3437943): Eli Lilly
  • 12.12.1. Drug Description
  • 12.12.2. Clinical Development
    • 12.12.2.1. Clinical Trial Information
  • 12.12.3. Safety and Efficacy
  • 12.12.4. Analyst's View
• 12.13. Lepodisiran (LY3819469): Eli Lilly
  • 12.13.1. Drug Description
  • 12.13.2. Other Developmental Activities
  • 12.13.3. Clinical Development
    • 12.13.3.1. Clinical Trial Information
  • 12.13.4. Safety and Efficacy
  • 12.13.5. Analyst's View
• 12.14. Olezarsen: Ionis Pharmaceuticals
  • 12.14.1. Drug Description
  • 12.14.2. Other Developmental Activities
  • 12.14.3. Clinical Development
    • 12.14.3.1. Clinical Trials Information
  • 12.14.4. Safety and Efficacy
  • 12.14.5. Analyst's View
• 12.15. Milvexian (BMS-986177; JNJ-70033093): Janssen Research & Development/Bristol-Myers Squibb
  • 12.15.1. Drug Description
  • 12.15.2. Other Developmental Activities
  • 12.15.3. Clinical Development
    • 12.15.3.1. Clinical Trials Information
  • 12.15.4. Analyst's View
• 12.16. Ziltivekimab (COR 001): Novo Nordisk
  • 12.16.1. Drug Description
  • 12.16.2. Other Developmental Activity
  • 12.16.3. Clinical Development
    • 12.16.3.1. Clinical Trials Information
  • 12.16.4. Safety and Efficacy
  • 12.16.5. Analyst's View
• 12.17. Dalcetrapib: DalCor Pharmaceuticals
  • 12.17.1. Drug Description
  • 12.17.2. Other Developmental Activities
  • 12.17.3. Clinical Development
    • 12.17.3.1. Clinical Trial Information
  • 12.17.4. Safety and Efficacy
  • 12.17.5. Analyst's View
• 12.18. Asundexian (BAY2433334): Bayer
  • 12.18.1. Drug Description
  • 12.18.2. Other Developmental Activities
  • 12.18.3. Clinical Development
    • 12.18.3.1. Clinical Trial Information
  • 12.18.4. Analyst's View
• 12.19. Zodasiran: Arrowhead Pharmaceuticals
  • 12.19.1. Drug Description
  • 12.19.2. Other Developmental Activities
  • 12.19.3. Clinical Development
    • 12.19.3.1. Clinical Trial Information
  • 12.19.4. Safety and Efficacy
  • 12.19.5. Analyst's View
• 12.2. Zilebesiran: Alnylam Pharmaceuticals/Roche
  • 12.20.1. Drug Description
  • 12.20.2. Other Developmental Activities
  • 12.20.3. Clinical Development
    • 12.20.3.1. Clinical Trial Information
  • 12.20.4. Analyst's View
• 12.21. Vicagrel: Jiangsu Vcare Pharmaceutical Technology
  • 12.21.1. Drug Description
  • 12.21.2. Other Developmental Activities
  • 12.21.3. Clinical Development
    • 12.21.3.1. Clinical Trial Information
  • 12.21.4. Analyst's View

13. ASCVD: 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Key Market Forecast Assumptions
  • 13.3.1. Cost Assumptions
• 13.4. Conjoint Analysis
• 13.5. Total Market Size of ASCVD in the 7MM
• 13.6. Total Market Size of ASCVD by Therapies in the 7MM
• 13.7. The United States
  • 13.7.1. Total Market Size of ASCVD
  • 13.7.2. Market Size of ASCVD by Therapies in the United States
• 13.8. EU4 and the UK
  • 13.8.1. Total Market Size of ASCVD
  • 13.8.2. Market Size of ASCVD by Therapies in EU4 and the UK
• 13.9. Japan
  • 13.9.1. Total Market Size of ASCVD
  • 13.9.2. Market Size of ASCVD by Therapies in Japan

14. Unmet Needs of ASCVD

15. SWOT Analysis of ASCVD

16. KOL Views of ASCVD

17. Market Access and Reimbursement of ASCVD

• 17.1. The United States
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Market Access and Reimbursement of ASCVD

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight